US2014242082A1PendingUtilityA1

Combination therapy for the treatment of ocular neovascular disorders

62
Assignee: OPHTHOTECH CORPPriority: Aug 27, 2003Filed: Feb 21, 2014Published: Aug 28, 2014
Est. expiryAug 27, 2023(expired)· nominal 20-yr term from priority
Inventors:David ShimaPerry CaliasAnthony P. Adamis
A61P 9/10A61P 43/00A61P 9/00A61P 27/02A61P 29/00A61P 27/06A61P 17/06A61P 19/02A61K 45/06A61K 39/3955A61K 39/395A61K 31/506C12N 15/1136A61K 2039/505A61K 31/52A61K 31/7088A61K 31/00C12N 15/11A61K 38/00A61K 31/519
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder.

Claims

exact text as granted — not AI-modified
1 - 18 . (canceled) 
     
     
         19 . A composition comprising an effective amount of:
 (a) a PDGF antagonist, wherein the PDGF antagonist is an antibody or binding fragment thereof; and   (b) a VEGF antagonist, wherein the VEGF antagonist is an antibody or binding fragment thereof.   
     
     
         20 . The composition of  claim 19 , wherein the PDGF antagonist is a PDGF-B antagonist. 
     
     
         21 . The composition of  claim 19 , wherein the PDGF antagonist is a PDGFR antagonist. 
     
     
         22 . The composition of  claim 21 , wherein the PDGFR antagonist is a PDGFR-beta antagonist. 
     
     
         23 . The composition of  claim 19 , wherein the VEGF antagonist is an anti-VEGF antibody or binding fragment thereof. 
     
     
         24 . The composition of  claim 23 , wherein the anti-VEGF antibody or binding fragment thereof binds to VEGF-A. 
     
     
         25 . The composition of  claim 24  wherein the anti-VEGF antibody or binding fragment thereof binds to human VEGF-A. 
     
     
         26 . The composition of  claim 23 , wherein the anti-VEGF antibody or binding fragment thereof has:
 (i) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 26 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 27, or   (ii) a light chain variable domain comprising the sequence of SEQ ID NO: 25 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 24.   
     
     
         27 . The composition of  claim 19 , wherein the VEGF antagonist is 2C3. 
     
     
         28 . The composition of  claim 21 , wherein the PDGFR antagonist is APB5.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.